Jennifer J. Linderman

This paper uses an agent-based model to show that immune activation and target-independent mechanisms significantly contribute to the efficacy of the ADC T-DXd in cancer therapy.

This study develops HALA antibodies that adjust ADC delivery based on tumor HER2 expression, improving efficacy across varying expression levels in preclinical models.

The paper simulates TB antibiotic regimens in a computational model to show rankings are influenced by spatial scale, detection limit, and initial bacterial burden.

The paper develops a whole-host model of Mtb infection to predict immune outcomes and shows blood biomarkers may only reflect early lung events.

This paper links drug transcriptomics with pharmacokinetics to predict in vivo drug interactions for tuberculosis treatments.